Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor

BACKGROUND: Ivacaftor approval was extended to people with cystic fibrosis (CF) and an R117H variant in 2014 in the USA. This observational, real-world, postapproval study evaluated long-term outcomes among people with CF and an R117H variant on ivacaftor using data from the US Cystic Fibrosis Found...

Descripción completa

Detalles Bibliográficos
Autores principales: Higgins, Mark, Farietta, Thalia, Campbell, Daniel, Liu, Meng, Ostrenga, Josh, Elbert, Alexander, Shih, Judy, Volkova, Nataliya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231020/
https://www.ncbi.nlm.nih.gov/pubmed/37230763
http://dx.doi.org/10.1136/bmjresp-2022-001447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231020/
https://www.ncbi.nlm.nih.gov/pubmed/37230763
http://dx.doi.org/10.1136/bmjresp-2022-001447

Ejemplares similares